NanoCor intends to use its proprietary Biological Nanoparticle technology platform and a proprietary, patent-protected gene to provide Chronic Heart Failure patients worldwide with an effective, economic, and safe alternative.
NanoLife Holdings is focused on its mission of the development of a Global Initiative, the commitment of the world's scientific, economic, and political prowess to Saving Lives from the Ravages of Cancer. NanoLife is facilitating advanced developments in radiotherapy for cancer.
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate the delivery of foreign DNA into living cells.
nanoTools provides monoclonal and polyclonal antibody development services and products. Besides providing individually tailored custom solutions, the company develops, manufactures and markets phosphorylation and modification - state specific monoclonal antibodies and other innovative reagents for Signal Transduction and Alzheimer research, high throughput screening (HTS) and proteomics.
NST is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents (ApoSense - a small molecule 'Interfacial Nanoswitch') based on the identification and targeting of cells undergoing apoptosis.
Piercell is a nanotechnology venture that is developing a biomolecular delivery device that pierces into primary and other hard-to-transfect cells. Piercell's vision is to pave the path to cell therapy by enabling ex vivo DNA and RNA drug delivery into clinically relevant cells of patients.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.
SurModics® Synthetic ECM is a synthetic, stable, and scalable cell culture platform that provides an in vivo-like cell culture environment with its biomimetic extracellular matrix structure and surface. The technology produces results for cell research and cell-related applications. The nanofibrillar matrix utilizes Ultra-Web™ technology.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.